SRDX - Surmodics, Inc.
| Previous Close | 38.70 |
| Open | 38.85 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 37.45 - 39.50 |
| 52 Week Range | 22.35 - 40.30 |
| Volume | 60,893 |
| Avg. Volume | 41,904 |
| Market Cap | 495.532M |
| Beta | 0.28 |
| PE Ratio (TTM) | 18,775.00 |
| EPS (TTM) | 0.00 |
| Earnings Date | Nov 14, 2017 - Nov 20, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 41.10 |
- Business Wire•21 hours ago
Surmodics Announces FDA Clearance of a New .018” Low-Profile PTA Balloon Dilation Catheter
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it received U.S. Food and Drug Administration 510 clearance for its .018” Low-Profile percutaneous transluminal angioplasty balloon dilation catheter, designed and indicated for a broad range of peripheral vascular applications.
- Thomson Reuters StreetEvents•14 days ago
Edited Transcript of SRDX presentation 27-Mar-18 6:30pm GMT
Surmodics Inc at Needham Healthcare Conference
- Zacks•15 days ago
SRDX or HAE: Which is a Better Medical Product Stock?
Here we analyze the financials and fundamental factors of Haemonetics (HAE) and Surmodics (SRDX) to decide which is a better investment option.
- Zacks•20 days ago
Here's Why You Should Invest in Surmodics (SRDX) Right Now
Surmodics (SRDX) continues to benefit from solid growth in the In Vitro Diagnostics (IVD) segment.
- GlobeNewswire•last month
Research Report Identifies Alamo Group, Surmodics, Nicolet Bankshares, Carriage Services, Terra Nitrogen Company, and Waterstone Financial with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, March 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Zacks•last month
Can The Uptrend Continue for Surmodics (SRDX)?
Investors certainly have to be happy with Surmodics, Inc. (SRDX) and its short term performance
- Zacks•last month
Zacks.com highlights: Copart, Haemonetics, Surmodics, Alarm.com Holdings and ConocoPhillips
Zacks.com highlights: Copart, Haemonetics, Surmodics, Alarm.com Holdings and ConocoPhillips
- Zacks•last month
5 Top-Ranked Efficient Stocks to Boost Your Portfolio
A company with a favorable efficiency level will provide impressive returns irrespective of market conditions
- Business Wire•last month
Surmodics to Present at Upcoming Investor Conferences
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and information systems and chief financial officer, will be attending two upcoming investor conferences in New York City.
- Zacks•2 months ago
3 Stocks to Gain as Trump Pulls Plug on Infamous MedTech Tax
Here take a quick look on three major MedTech companies that are going to make the best out of the recent Tax-Repeal upheaval.
Market Realist•2 months agoAbbott Laboratories Enters Collaboration Agreement with Surmodics
On February 27, 2018, Abbott Laboratories (ABT) and Surmodics (SRDX) announced that the two companies have entered an agreement for the commercialization rights of Surmodics’ SurVeil DCB (drug-coated balloon) for the treatment of superficial femoral artery. As per the agreement, Abbott Laboratories will gain exclusive commercial rights for the SurVeil DCB, which is currently in clinical trials. Surmodics will supply the device to Abbott once approved.
- Zacks•2 months ago
Abbott to Strengthen Vascular Care Arm With Surmodics Deal
Abbott (ABT) gains traction from its newly acquired rights over the SurVeil drug-coated balloon, which shows greater potential for capturing the market compared with traditional devices.
- American City Business Journals•2 months ago
Surmodics, Abbott ink licensing deal worth up to $92M
Med-tech firm Surmodics Inc. has landed a licensing deal with health care giant Abbott Laboratories Inc. that could be worth up to $92 million, the companies announced Tuesday. Eden Prairie-based Surmodics will exclusively license its SurVeil drug-coated balloon device to Abbott (ABT). Surmodics is testing the device as a treatment for peripheral artery disease.
- PR Newswire•2 months ago
Abbott and Surmodics Announce Agreement for Next-Generation Drug-Coated Balloon
- COMPANIES TO COLLABORATE ON PRODUCT DEVELOPMENT, CLINICAL TRIALS AND REGULATORY ACTIVITIES TO OBTAIN APPROVAL IN U.S. AND E.U. ABBOTT PARK, Ill. and EDEN PRAIRIE, Minn., Feb. 27, 2018 /PRNewswire/ -- Abbott (ABT) and Surmodics (SRDX) today announced that the companies have entered into an agreement whereby Abbott will have exclusive worldwide commercialization rights for Surmodics' SurVeil® drug-coated balloon to treat the superficial femoral artery, which is currently being evaluated in a U.S. pivotal clinical trial.
- Business Wire•2 months ago
Surmodics to Host Virtual Annual Meeting of Shareholders
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Wednesday, February 21, at 4:00 p.m. CT , as a virtual meeting.
- Zacks•2 months ago
Surmodics (SRDX) Beats on Earnings in Q1, Guidance Solid
Solid performance in the In Vitro Diagnostics segment drives Surmodics (SRDX) in first-quarter fiscal 2018.
- Associated Press•2 months ago
SurModics reports 1Q loss
The Eden Prairie, Minnesota-based company said it had a loss of 12 cents per share. Earnings, adjusted for pretax expenses and non-recurring costs, were 10 cents per share. The drug delivery technology ...
- Business Wire•2 months ago
Surmodics Reports First Quarter Fiscal 2018 Results, Updates Fiscal 2018 Guidance
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 first quarter, ended December 31, 2017, and updated financial outlook for fiscal 2018.
- Business Wire•3 months ago
Surmodics to Webcast First Quarter Fiscal 2018 Earnings Conference Call on February 8
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal 2018 conference call on Thursday, February 8, at 7:30 a.m.
- Business Wire•3 months ago
Surmodics Receives 510(K) Clearance for Telemark™ Coronary/Peripheral Support Microcatheter from the U.S. Food and Drug Administration
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration 510 clearance for its Telemark™ .014” coronary and peripheral support microcatheter.
- Zacks•3 months ago
Surmodics (SRDX) Poised on Core Business Amid Forex Woes
Surmodics' (SRDX) top line benefits from strong sales in Medical Device and IVD businesses. However, foreign currency is a headwind.
- Zacks•3 months ago
New Strong Sell Stocks for January 8th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
- Capital Cube•5 months ago
SurModics, Inc. breached its 50 day moving average in a Bearish Manner : SRDX-US : December 8, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for SurModics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
